Skip to main content

Sialorrhea

6
Pipeline Programs
4
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
5
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Supernus Pharmaceuticals
3 programs
3
MYOBLOCPhase 33 trials
MYOBLOCPhase 31 trial
MYOBLOC Low DosePhase 31 trial
Active Trials
NCT02610868Completed187Est. Jun 2017
NCT00515437Completed54Est. Sep 2008
NCT00702754Completed502Est. Sep 2008
+2 more trials
US WorldMeds
US WorldMedsKY - Louisville
2 programs
2
MYOBLOCPhase 3
MYOBLOCPhase 3
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
BOTULINUM NEUROTOXIN TYPE-APhase 2/31 trial
Active Trials
NCT01489904Unknown60Est. Nov 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Supernus PharmaceuticalsMYOBLOC
Supernus PharmaceuticalsMYOBLOC Low Dose
Supernus PharmaceuticalsMYOBLOC
Supernus PharmaceuticalsMYOBLOC
AbbVieBOTULINUM NEUROTOXIN TYPE-A
Supernus PharmaceuticalsMYOBLOC

Clinical Trials (6)

Total enrollment: 990 patients across 6 trials

NCT00702754Supernus PharmaceuticalsMYOBLOC

Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia

Start: Jun 2001Est. completion: Sep 2008502 patients
Phase 4Completed
NCT05097079Supernus PharmaceuticalsMYOBLOC Low Dose

Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects

Start: Nov 2021Est. completion: May 20230
Phase 3Withdrawn
NCT02610868Supernus PharmaceuticalsMYOBLOC

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

Start: Oct 2015Est. completion: Jun 2017187 patients
Phase 3Completed
NCT01994109Supernus PharmaceuticalsMYOBLOC

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

Start: Nov 2013Est. completion: Jan 2017187 patients
Phase 3Completed
NCT01489904AbbVieBOTULINUM NEUROTOXIN TYPE-A

Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy

Start: Nov 2011Est. completion: Nov 201260 patients
Phase 2/3Unknown
NCT00515437Supernus PharmaceuticalsMYOBLOC

A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

Start: Jul 2007Est. completion: Sep 200854 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.